Ovarian cancer is a cancer that begins in an ovary.

We have more trials planned for lung cancer, pancreatic cancer, ovarian cancer and breast cancer.

These women also run a greater risk of ovarian cancer.

And this is exactly how one cancer cell becomes two cancer cells, two cancer cells become four cancer cells, and we have ultimately uncontrolled tumor growth.

In prostate cancer, the cells of these prostate glands mutate into cancer cells.

Two years later, she comes back with stage three C ovarian cancer.

Jolie s mother, Marcheline Bertrand, died at 56 from a related illness, ovarian cancer.

Maria Reiche died of ovarian cancer on June 8, 1998, in an air force hospital in Lima.

Cancer stem cells (CSCs) are cancer cells (found within tumors or hematological cancers) that possess characteristics associated with normal stem cells, specifically the ability to give rise to all cell types found in a particular cancer sample.

Method One approach to cancer vaccination is to separate proteins from cancer cells and immunize cancer patients against those proteins, in the hope of stimulating an immune reaction that could kill the cancer cells.

To test this idea, we treated a human ovarian cancer, grown in mice, with conventional high dose chemotherapy.

The tissue is analyzed for the presences of cancer cells.

Dozens of their mutations are associated with an increased risk of hereditary breast and ovarian cancer. Women who have an abnormal BRCA1 or BRCA2 gene run a lifetime risk of up to 85 of developing breast cancer, while the increased risk of developing ovarian cancer is about 55 for women with BRCA1 mutations and about 25 for women with BRCA2 mutations.

Cancer cells pay a price when they evolve resistance to chemotherapy.

This is because cancer stem cells are isolated from end stage tumors.

A transscrotal biopsy or orchiectomy will potentially leave cancer cells in the scrotum and create two routes for cancer cells to spread, while in an inguinal orchiectomy only the retroperitoneal route exists.

Likewise, it has facilitated important innovations, such as pharmacogenetic cancer treatment, in which drugs target specific genetic defects within cancer cells.

This function also extends to cancer cells, and regulating their movement and proliferation of cancer to other parts of the body.

The cancer cells, small, round and rapidly dividing, grew these arms and extensions.

Just as invasive species adapt to pesticides, most cancer cells adapt to therapies.

That cancer cells pay a price for resistance is supported by several observations.

This constitutes the use of agents specific for the deregulated proteins of cancer cells.

Although the gene s function in causing breast and ovarian cancer was uncovered by Cancer Research UK in 1995, Myriad, along with nearly 30 other defendants, argues that the patent is a necessary reward for its research costs.

Targeted therapy Targeted therapy, according to the National Cancer Institute, is a type of treatment that uses drugs or other substances, such as monoclonal antibodies, to identify and attack specific cancer cells without harming normal cells.

The discovery could also work to prevent hereditary breast cancer cells from growing into tumors.

Cancer cells can also metastasize (spread) from their original site to other parts of the body.

Our models show that in the absence of therapy, cancer cells that haven t evolved resistance will proliferate at the expense of the less fit resistant cells.

In cancer research experiments, tumor cells are sometimes injected into an experimental animal to establish a tumor.

Gestational trophoblasts are of particular interest to cell biologists because, like cancer, these cells invade tissue (the uterus), but unlike cancer, they sometimes know when to stop.

Treating women carrying BRCA1 or BRCA2 mutations with PARP inhibitors to kill cancer cells before they grow into tumors is a new and hopeful concept in cancer prevention.

Some researchers believe that cancer cells routinely arise and are destroyed by the healthy immune system and that cancer forms when the immune system fails to destroy them.

And the same vessels that are feeding tumors allow cancer cells to exit into the circulation as metastases.

Researchers will need to establish the mechanisms by which cancer cells achieve resistance and what it costs them.

Cancer cells mutate and they gain the ability to release lots of those angiogenic factors, natural fertilizer, that tip the balance in favor of blood vessels invading the cancer.

Women carrying a mutated BRCA1 or BRCA2 gene have roughly an 80 risk of developing breast cancer. A mutation in these genes also leads to an increased risk of developing ovarian tumors.

Or imagine a simple and inexpensive urine test that can diagnose cancer, eliminating the need for a surgical biopsy. And, when cancer treatment is needed, its toxic punch hits cancer cells selectively, with far fewer damaging side effects.

And, two weeks before Martin died, Jolie revealed that she had undergone a preventive double mastectomy after testing positive for a BRCA gene mutation which is correlated with a woman s being five times more susceptible to breast cancer and 28 times more susceptible to ovarian cancer.

And, unfortunately, this late stage of cancer is the one at which it's most likely to be diagnosed, when angiogenesis is already turned on and cancer cells are growing like wild.

In our research, we exploit this requirement to specifically target the BRCA1 or BRCA2 defective cancer cells with inhibitors of PARP.

Lung cancer cells that are resistant to the chemotherapy gemcitabine are less proliferative, invasive, and motile than their drug sensitive counterparts.

The first useful applications of nanomachines might be in medical technology, which could be used to identify and destroy cancer cells.

The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.

If those diseases where tissues are deteriorating for example Alzheimer's, where the brain, the brain cells, die and we need to restore new brain cells, new functional brain cells what if we could, in the future, use cancer? A tumor put it in the brain and cause it to differentiate into brain cells?

In the United States, health insurers cover the cost only if a first degree relative for example, a woman s mother has had a history of breast or ovarian cancer other women must pay out of pocket.

So just finally, cancer is an inevitable outcome of the ability of our cells to divide and to adapt to their environments.